Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
7.19
+0.84 (13.23%)
Nov 6, 2026, 4:00 PM EST - Market closed
Satellos Bioscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
152.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Sutro Biopharma | 45.70M |
| Atrium Therapeutics | 35.84M |
| Zentalis Pharmaceuticals | 26.87M |
| Oramed Pharmaceuticals | 2.00M |
MSLE News
- 1 day ago - Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results - MarketBeat
- 2 days ago - Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027 - Nasdaq
- 2 days ago - Satellos Bioscience Transcript: Study update - Transcripts
- 2 days ago - Satellos Bioscience Press release: Study update - Filings
- 2 days ago - Satellos Bioscience Slides: Study update - Filings
- 2 days ago - Satellos changes primary endpoint in BASECAMP trial after FDA feedback - TheFly
- 2 days ago - Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback - GlobeNewsWire
- 2 days ago - Satellos Bioscience Slides: Corporate presentation - Filings